PRESCIENT THERAPEUTICS
Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
PRESCIENT THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Oncology Pharmaceutical Precision Medicine Therapeutics
Founded:
1999-01-01
Address:
South Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.ptxtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+61396927222
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
SPF Amazon Amazon Virginia Region NameBright
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Elevation Oncology
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
FogPharma
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Kura Oncology
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Merus
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.ptxtherapeutics.com Semrush global rank: 11.55 M Semrush visits lastest month: 203
- Host name: 172.67.148.216
- IP address: 172.67.148.216
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Prescient Therapeutics"
Home - PTX Therapeutics
Apr 9, 2024 · Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.See details»
About Us - PTX Therapeutics
Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s …See details»
Technology - PTX Therapeutics
Prescient Therapeutics is developing personalised medicine approaches to cancer, including cell therapies and targeted therapies. PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known …See details»
Prescient Therapeutics - Overview, News & Similar companies
Mar 6, 2024 · Prescient Therapeutics contact info: Phone number: +61 396927222 Website: www.ptxtherapeutics.com What does Prescient Therapeutics do? Prescient Therapeutics is a …See details»
Prescient Therapeutics - Crunchbase Company Profile & Funding
Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological …See details»
Investor Centre - PTX Therapeutics
Apr 9, 2024 · Here you can find all the latest ASX announcements, news, company information and presentations, reports and up-to-the-minute share price and information. Prescient Therapeutics develops personalised therapies to …See details»
Creating next-gen cell therapies that are controllable, flexible ...
CellPryme: Technology for enhancing Cell Therapy Manufacture and Clinical Efficacy. Any Immune Cell → To any Target... of targeting ligand... Modular and covalent architecture of …See details»
Ptxtherapeutics.com Home - PTX Therapeutics - HypeStat
Title:Home - PTX TherapeuticsDescription:Prescient is an ASX-listed biotechnology company focused on improving outcomes for *** patients by developing, licencing and collaborating on …See details»
Prescient Therapeutics Initiates Phase 1b Clinical Trial for
Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia. Highlights:See details»
Pipeline - PTX Therapeutics
Prescient has licensed technologies from and collaborates with world-leading cancer centres in the US and Australia. Targeted therapy: PTX-100. PTX-100 is a first in class compound with the ability to block an important cancer growth …See details»
PTX.AX - | Stock Price & Latest News | Reuters
Nov 21, 2024 · Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including …See details»
Prescient Therapeutics - Facebook
Prescient Therapeutics. 923 likes · 1 talking about this. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised...See details»
US FDA Grants Orphan Drug Designation
Mar 9, 2023 · TX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts. oncogenic Ras …See details»
ptxtherapeutics.com Reviews: Is this site a scam or legit?
We put to work 53 powerful factors to expose high-risk activity and see if ptxtherapeutics.com is a scam. Let's look at it and its industry through an in-depth review. You'll also learn how to …See details»
News and Media - PTX Therapeutics
Sep 5, 2024 · Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific ... Register your details to receive …See details»
PTX-200 AML Trial Progresses to Higher Dose
Apr 23, 2021 · PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including …See details»
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine ...
Jun 6, 2018 · PTx is an integrated commercial-stage biotech company focused on the development and commercialization of therapeutics that improve health and economic …See details»
PTX-100 investor update and additional patient response
Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn. The Board of Prescient Therapeutics Limited has approved the release of this …See details»
Appendix 4G Key to Disclosures Corporate Governance Council …
Https://ptxtherapeutics.com/investors/corporate-governance/ The Corporate Governance Statement is accurate and up to date as at 26 August 2019 and has been approved by the board.See details»
PTX-100 investor update and additional patient response …
Nov 2, 2022 · Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn. The Board of Prescient Therapeutics Limited has approved the …See details»